We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

New Standardized Whole Genomes Released to Improve Quality Control

By LabMedica International staff writers
Posted on 26 Sep 2016
Print article
Image: A scanning electron micrograph (SEM) shows an oral squamous cancer cell (white) being attacked by two cytotoxic T-cells (red). The tumor-specific T-cells were developed from the patient’s own immune system, a “personalized cancer vaccine” like those that may be developed in the future with the help of NIST’s standardized human genomes as reference materials (Photo courtesy of R.E. Serda / NCI).
Image: A scanning electron micrograph (SEM) shows an oral squamous cancer cell (white) being attacked by two cytotoxic T-cells (red). The tumor-specific T-cells were developed from the patient’s own immune system, a “personalized cancer vaccine” like those that may be developed in the future with the help of NIST’s standardized human genomes as reference materials (Photo courtesy of R.E. Serda / NCI).
Researchers have expanded the set of tools for more accurate next generation sequencing (NGS) analysis of genomes by developing 4 additional reference materials (RMs) to run as controls for assessing performance of the equipment, chemistry, and data analysis being used.

With the addition of genome RMs to a growing collection of “measuring sticks” for DNA sequencing, the National Institute of Standards and Technology (NIST; Gaithersburg, MD, USA) can now provide laboratories with even more capability to map DNA for genetic testing, medical diagnoses, and development of customized drug therapies. The new RMs feature human genomes for 1 Asian and 3 Ashkenazic Jewish individuals, as well as one RM made up of four microbes commonly used in research.

RMs are critical to properly evaluate NGS and genetic testing methods to increase reliability and effectiveness of precision medicine (personalized medicine). The NIST RMs provide well-characterized, whole genome standards that can help a laboratory evaluate how well its DNA sequencing processes are working.

Biases and "blind spots” for certain sequences contribute to uncertainties or errors in the sequence analysis. These biases can lead to hundreds of thousands of disagreements about the same genome. To better understand these biases, laboratories can now compare their results to the information provided by NIST. The RMs have been extensively characterized with multiple techniques, with the results weighted and analyzed to eliminate as much bias and error as possible.

In 2015, the NIST issued the first genome RM (NIST RM 8398) —detailing the genetic makeup for a woman with European ancestry. The 4 new RMs are: NIST RM 8391: male of Eastern European Ashkenazic Jewish ancestry; NIST RM 8392: son (same as NIST RM 8391), father, and mother who are a family of Eastern European Ashkenazic Jewish ancestry; NIST RM 8393: male of East Asian (Chinese) ancestry; and NIST RM 8375: genomes for 4 bacterial species: Salmonella typhimurium LT2, Staphylococcus aureus, Pseudomonas aeruginosa, and Clostridium sporogenes.

The individual human RMs provide a baseline for comparing and contrasting genes from distinctly different lineages, while the trio mother-father-son RM aids analysis of genetic links between family members. The bacterial genomes come from species that challenge the technical performance of sequencing methods and have been determined by the US Food and Drug Administration (FDA) to have significant relevance to the research of public health issues such as food contamination, antibiotic resistance, and hospital-acquired infections.

The RMs can help increase the ability of DNA sequencing laboratories to be more confident in their reporting of true vs. false positives, and true vs. false negatives, and therefore significantly improve genetic tests used for disease risk prediction, diagnosis, and progression tracking. They also can be used with tools developed by the “Global Alliance for Genomics and Health Benchmarking Team” to further raise confidence level.

Similarly, the standardized microbial genomes in NIST RM 8375 can be used to assess performance of high-throughput methods for microbial DNA sequencing.

The RMs were created by NIST and its partners in the Genome in a Bottle consortium, a group that includes members from the federal government, academia, and industry. The consortium is managed by the Joint Initiative for Metrology in Biology (JIMB), a collaboration between NIST and Stanford University. Through its effort to develop, produce, and distribute a suite of genome RMs, the consortium is providing medical and research laboratories with tools to advance clinical applications of whole genome sequencing, and the FDA with better capability to conduct science-based regulatory oversight of the technology.

All five RMs are available for purchase from the NIST Standard Reference Material program. Each RM sample is characterized for homogeneity (to ensure that each vial contains similar DNA) and stability (to ensure comparability to future batches). The original sources for the RMs are from the “Personal Genome Project,” whose cell lines are hosted at the Coriell Institute for Medical Research.

Next additions to the RM collection may include whole genomes from persons with Hispanic, African, and mixed ancestries, as well as a set containing sequenced genes of both malignant tumor and normal cells from the same individual.

Related Links:
National Institute of Standards and Technology


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.